Part: 12         Session: 145678910111213141516171819202122         Page 861862863864865866867868869870871872873874875876877878879880881882883884885886887888889890891892893894895896897898899900901902903904905906907908909910911912913914915916917918919920921922923924925926927928929930 of 999

They are in existence, but they haven't been tried except in most instances -- they haven't been tried on any scale except in animals, and there are a variety of them, some better known than others, largely because they have been known but never patented by a drug house and made; so that if a patent period has run out, there's been a patent and it's run out and it's never been tried clinically, other drug houses don't want to do anything on it. It's going to be very complicated if I can't get some drug houses interested in them by some device, to get orphan drugs supported by the federal government. But he is extremely interested. His name is Robert Butler.

Now, Cranston is very interested.

Yes, you told me last year that Cranston was very interested.

Interested in aging and felt that the Institute on Aging wasn't doing enough about the drugs and was not aggressive enough, and I think this has stimulated Butler to some extent

Didn't Cranston have a separate committee or something?

He had a committee called FIBER: Fund for Integrated Biomedical Research. He's raising money for it, and he's got four or five employees, especially a man called Regelson, Dr. Regelson, who has a lot of ideas in this field. He's very